Profound Medical Inc.

Profound Medical Corp. is a medical technology platform company traded on the TSX under the stock ticker PRN and on NASDAQ under the stock ticker PROF. Profound is focused on the development and commercialization of proprietary, magnetic resonance guided focused ultrasound devices that provide incision free ablative technology to clinicians targeting various unmet needs of patients in multiple anatomies and disease states. The Company has two MRI-guided ultrasound ablation platforms, TULSA-PRO currently focused on ablating prostate cancer, and Sonalleve which is currently focused on treating uterine fibroids. Both platforms are currently approved and being commercialized in various jurisdictions.